Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study
- 31 July 2011
- journal article
- research article
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 11 (7), 507-515
- https://doi.org/10.1016/s1473-3099(11)70098-6
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Host Genetic Determinants of T Cell Responses to the MRKAd5 HIV-1 gag/pol/nef Vaccine in the Step TrialThe Journal of Infectious Diseases, 2011
- Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccineCurrent Opinion in HIV and AIDS, 2010
- Response definition criteria for ELISPOT assays revisitedCancer Immunology, Immunotherapy, 2010
- Functional properties and epitope characteristics of T-cells recognizing natural HIV-1 variantsVaccine, 2009
- HIV molecular epidemiology: transmission and adaptation to human populationsCurrent Opinion in HIV and AIDS, 2009
- Uptake of Male Circumcision in an HIV Vaccine Efficacy TrialJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysisThe Lancet, 2008
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialThe Lancet, 2008
- HIV Type 1 Subtype CgagandnefDiversity in Southern AfricaAIDS Research and Human Retroviruses, 2007
- The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populationsAIDS, 2001